UY35454A - Muteínas de interleucina-2 para la expansión de células t reguladoras - Google Patents

Muteínas de interleucina-2 para la expansión de células t reguladoras

Info

Publication number
UY35454A
UY35454A UY0001035454A UY35454A UY35454A UY 35454 A UY35454 A UY 35454A UY 0001035454 A UY0001035454 A UY 0001035454A UY 35454 A UY35454 A UY 35454A UY 35454 A UY35454 A UY 35454A
Authority
UY
Uruguay
Prior art keywords
muteins
cells
interleucine
regulating
expansion
Prior art date
Application number
UY0001035454A
Other languages
English (en)
Inventor
Li Li
Marc A Gavin
Kannan Gunasekaran
Joshua T Pearson
Karow Margaret
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of UY35454A publication Critical patent/UY35454A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente se proporcionan muteínas de la IL-2 y moléculas de fusión Fc de muteína de la IL-2 que preferentemente se expanden y activan las células reguladoras T y son susceptibles a producción a gran escala. También se proporcionan en la presente moléculas de Fc de IgG1 humana que carecen de o con función efectora altamente reducida y alta estabilidad a pesar de la falta de glicosilación en N297. También, se proporcionan en la presente péptidos enlazadores que están glicosilados cuando se expresan en células de mamífero.
UY0001035454A 2013-03-14 2014-03-14 Muteínas de interleucina-2 para la expansión de células t reguladoras UY35454A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361784669P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
UY35454A true UY35454A (es) 2014-09-30

Family

ID=50680166

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035454A UY35454A (es) 2013-03-14 2014-03-14 Muteínas de interleucina-2 para la expansión de células t reguladoras

Country Status (40)

Country Link
US (7) US9546203B2 (es)
EP (2) EP2970423B1 (es)
JP (5) JP6480409B2 (es)
KR (4) KR20230157526A (es)
CN (2) CN105143253B (es)
AP (1) AP2015008737A0 (es)
AR (1) AR095541A1 (es)
AU (2) AU2014236281B2 (es)
BR (1) BR112015022440B1 (es)
CA (3) CA2906708C (es)
CL (2) CL2015002669A1 (es)
CR (2) CR20200004A (es)
CY (2) CY1121767T1 (es)
DK (2) DK2970423T3 (es)
EA (2) EA034326B1 (es)
ES (2) ES2737598T3 (es)
HK (1) HK1220695A1 (es)
HR (2) HRP20190970T1 (es)
HU (2) HUE044321T2 (es)
IL (2) IL241349B (es)
JO (1) JO3796B1 (es)
LT (2) LT2970441T (es)
MA (2) MA38477B1 (es)
ME (2) ME03437B (es)
MX (2) MX2015012890A (es)
MY (2) MY202248A (es)
NZ (1) NZ751148A (es)
PE (1) PE20151763A1 (es)
PH (1) PH12015502051A1 (es)
PL (2) PL2970423T3 (es)
PT (2) PT2970441T (es)
RS (2) RS58854B1 (es)
SG (2) SG11201507574VA (es)
SI (2) SI2970441T1 (es)
TN (1) TN2015000416A1 (es)
TR (2) TR201910802T4 (es)
TW (3) TWI687435B (es)
UA (1) UA119140C2 (es)
UY (1) UY35454A (es)
WO (2) WO2014153063A1 (es)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US20190202898A9 (en) * 2012-04-03 2019-07-04 Novelmed Therapeutics, Inc. AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
WO2014055835A1 (en) * 2012-10-04 2014-04-10 Novelmed Therapeutics, Inc. Alternative pathway specific antibodies for treating hemolytic diseases
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
SG11201507429TA (en) * 2013-03-15 2015-10-29 Genentech Inc Il-22 polypeptides and il-22 fc fusion proteins and methods of use
ES2770976T3 (es) 2013-03-15 2020-07-06 Amgen Inc Anticuerpos PAC1 humanos
DK3102595T3 (en) 2014-02-06 2019-02-04 Hoffmann La Roche Interleukin-2 fusion proteins and their applications
JP6768633B2 (ja) * 2014-07-21 2020-10-14 デリニア， インコーポレイテッド 自己免疫疾患を治療するために調節性ｔ細胞を選択的に活性化する分子
CN113234138A (zh) 2014-08-11 2021-08-10 德里尼亚公司 选择性地活化调节性t细胞用于治疗自身免疫病的修饰的il-2变体
AU2015318008B2 (en) 2014-09-15 2021-05-20 Amgen Inc. Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof
US10793613B2 (en) * 2014-12-15 2020-10-06 Washington University Compositions and methods for targeted cytokine delivery
SG11201708349VA (en) * 2015-04-10 2017-11-29 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
US10851144B2 (en) 2015-04-10 2020-12-01 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
US10822408B2 (en) 2015-12-15 2020-11-03 Amgen Inc. PACAP antibodies and uses thereof
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
MD3411402T2 (ro) * 2016-02-03 2022-05-31 Amgen Res Munich Gmbh Constructe de anticorpi bispecifici BCMA și CD3 de angajare a celulei T
TN2018000266A1 (en) * 2016-02-03 2020-01-16 Amgen Res Munich Gmbh Psma and cd3 bispecific t cell engaging antibody constructs.
EA039859B1 (ru) * 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
KR20180117116A (ko) 2016-02-05 2018-10-26 워싱턴 유니버시티 표적화된 사이토카인 전달을 위한 조성물 및 방법들
CN107287273B (zh) * 2016-03-31 2021-03-09 复旦大学附属妇产科医院 表达Tim-3的外周血NK细胞在制备自然流产生物标记物中的用途
EP3443001A4 (en) 2016-04-11 2020-04-29 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
EP3808764A1 (en) * 2016-05-04 2021-04-21 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
JP7206190B2 (ja) 2016-06-22 2023-01-17 ダヴィド・クラッツマン 遺伝的に修飾されたｔリンパ球
WO2018027025A1 (en) * 2016-08-03 2018-02-08 Oncomed Pharmaceuticals, Inc. Cd40-binding agents and uses thereof
KR101928981B1 (ko) 2016-09-02 2018-12-13 고려대학교 산학협력단 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물
AU2017359172A1 (en) 2016-11-08 2019-05-16 Delinia, Inc. IL-2 variants for the treatment of autoimmune diseases
US11384336B2 (en) 2016-12-07 2022-07-12 East Carolina University Compositions and methods for in vitro cultivation and/or expansion of regulatory T cells
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
MX2019013517A (es) 2017-05-24 2020-08-17 Pandion Operations Inc Inmunotolerancia dirigida.
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
WO2019112852A1 (en) * 2017-12-06 2019-06-13 Pandion Therapeutics, Inc. Targeted immunotolerance
EA202090581A1 (ru) 2017-10-04 2020-08-31 Амген Инк. Продукты слияния транстиретина и иммуноглобулина
WO2019112854A1 (en) * 2017-12-06 2019-06-13 Pandion Therapeutics, Inc. Il-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
JP2021506291A (ja) 2017-12-19 2021-02-22 ゼンコア インコーポレイテッド 改変されたｉｌ−２ ｆｃ融合タンパク質
KR20200103681A (ko) 2017-12-27 2020-09-02 쿄와 기린 가부시키가이샤 Il-2 개변체
TWI831762B (zh) 2018-01-12 2024-02-11 美商安進公司 Pac1抗體及其用途
EP3752178A1 (en) 2018-02-16 2020-12-23 Iltoo Pharma Use of interleukin 2 for treating sjögren's syndrome
TW202003551A (zh) 2018-03-28 2020-01-16 美商必治妥美雅史谷比公司 介白素-2/介白素-2受體阿法融合蛋白及其使用方法
AU2019283621B2 (en) 2018-06-07 2023-03-30 Korea Research Institute Of Bioscience And Biotechnology Transgenic mouse for aglycosylated antibody production and use of aglycosylated antibody produced therefrom
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
KR20210038548A (ko) 2018-06-22 2021-04-07 큐진 인크. 사이토카인-기반 생체활성 약물 및 이의 사용 방법
US11530274B2 (en) 2018-07-02 2022-12-20 Amgen Inc. Anti-STEAP1 antigen-binding protein
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2020088164A1 (zh) * 2018-11-01 2020-05-07 山东新时代药业有限公司 双特异性抗体及其用途
WO2020163782A2 (en) 2019-02-08 2020-08-13 The Uab Research Foundation Immunotherapy for the treatment and prevention of inflammatory bowel disease
US11254736B2 (en) 2019-02-15 2022-02-22 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
WO2020168059A1 (en) 2019-02-15 2020-08-20 Integral Molecular, Inc. Claudin 6 antibodies and uses thereof
BR112021019178A2 (pt) 2019-03-29 2021-12-07 Centre Nat Rech Scient Variantes de interleucina-2 com atividade biológica modificada
CN111944036A (zh) * 2019-05-14 2020-11-17 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
TW202110885A (zh) 2019-05-20 2021-03-16 美商潘迪恩治療公司 靶向ＭＡｄＣＡＭ之免疫耐受性
CA3142440A1 (en) 2019-06-07 2020-12-10 Amgen Inc. Bispecific binding constructs
MX2021015976A (es) 2019-07-08 2022-02-10 Amgen Inc Fusiones de inmunoglobulina y transtiretina multiespecificas.
TW202118774A (zh) * 2019-07-26 2021-05-16 美商威特拉公司 介白素-2藥劑及其用途
EP4385573A2 (en) * 2019-08-13 2024-06-19 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
AU2020346580A1 (en) 2019-09-13 2022-03-31 Kyowa Kirin Co., Ltd. DcR3 variant
BR112022009521A2 (pt) * 2019-11-20 2022-08-16 Gi Cell Inc Composição de meio para cultura de células t e método para cultura de células t usando a mesma
WO2021108389A1 (en) * 2019-11-29 2021-06-03 Nkmax Co., Ltd. Method of producing natural killer cells and compositions thereof
CN115190885A (zh) 2019-12-12 2022-10-14 艾尔图制药公司 白细胞介素2嵌合构建体
CA3162705A1 (en) 2019-12-17 2021-06-24 Amgen Inc. Dual interleukin-2 /tnf receptor agonist for use in therapy
BR112022012112A2 (pt) 2019-12-20 2022-09-06 Regeneron Pharma Agonistas de il2 e métodos de uso dos mesmos
CN115362168A (zh) 2020-01-14 2022-11-18 辛德凯因股份有限公司 偏向化il2突变蛋白方法和组合物
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations Inc TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
CA3177843A1 (en) 2020-05-13 2021-11-18 John Thomas MULLIGAN Compositions of protein complexes and methods of use thereof
AU2021283933A1 (en) 2020-06-04 2023-01-05 Amgen Inc. Bispecific binding constructs
US20230226203A1 (en) * 2020-06-18 2023-07-20 Proviva Therapeutics (Hong Kong) Limited Activatable procytokines
CN112048018B (zh) * 2020-08-31 2021-10-08 南方医科大学 一种嵌合t细胞生长因子及其应用
CA3195260A1 (en) 2020-10-29 2022-05-05 Bristol-Myers Squibb Company Fusion proteins for the treatment of disease
WO2022120033A1 (en) 2020-12-03 2022-06-09 Amgen Inc. Immunoglobuline constructs with multiple binding domains
AU2021391924A1 (en) * 2020-12-04 2023-06-22 The General Hospital Corporation Methods of using interleukin-2 agents
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
TW202306584A (zh) 2021-05-27 2023-02-16 法商賽諾菲公司 具有對Fc受體之增強親和力及改良熱穩定性的Fc變體
EP4380970A1 (en) * 2021-08-06 2024-06-12 Amgen Inc. Isolation of therapeutic protein
IL311883A (en) 2021-10-06 2024-06-01 Assist Publique H?Pitaux De Paris Interleukin 2 chimeric constructs with targeted specificity for inflammatory tissues
AU2022366971A1 (en) 2021-10-14 2024-05-02 Teneobio, Inc. Mesothelin binding proteins and uses thereof
CA3234995A1 (en) * 2021-10-14 2023-04-20 Latticon (Suzhou) Biopharmaceuticals Co., Ltd. Novel antibody-cytokine fusion protein, preparation method therefor and use thereof
CA3238574A1 (en) * 2021-12-01 2023-06-08 Gregory Babcock Methods of using interleukin-2 agents
WO2023148397A1 (en) 2022-02-07 2023-08-10 Vib Vzw Engineered stabilizing aglycosylated fc-regions
WO2023164476A2 (en) * 2022-02-22 2023-08-31 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disorders
WO2023180527A1 (en) 2022-03-25 2023-09-28 Universität Zürich Adenoviral mediated targeting of activated immune cells
WO2023227790A1 (en) 2022-05-27 2023-11-30 Sanofi Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
WO2024026358A1 (en) 2022-07-27 2024-02-01 Teneobio, Inc. Mesothelin binding proteins and uses thereof
WO2024056154A1 (en) 2022-09-12 2024-03-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Interleukin-2 for use in treating autism spectrum disorder
WO2024077044A1 (en) 2022-10-05 2024-04-11 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
WO2024089609A1 (en) 2022-10-25 2024-05-02 Ablynx N.V. Glycoengineered fc variant polypeptides with enhanced effector function
WO2024151515A2 (en) 2023-01-09 2024-07-18 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447A (en) 1846-04-04 Car- wheel
US233A (en) 1837-06-14 Improvement in plows
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
EP0351410A1 (en) 1987-03-18 1990-01-24 3i RESEARCH EXPLOITATION LIMITED Complement-binding peptide
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
CA2062582C (en) 1991-03-27 1996-03-26 Tse-Wen Chang Methods and substances for recruiting therapeutic agents to solid tissues
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6239328B1 (en) 1992-10-05 2001-05-29 North Carolina State University Method for reducing expression variability of transgenes in plant cells
US6037525A (en) 1996-08-01 2000-03-14 North Carolina State University Method for reducing expression variability of transgenes in plant cells
FR2752462B1 (fr) 1996-08-14 1998-10-23 Essilor Int Procede d'incorporation d'additifs dans un article ophtalmique au moyen d'un fluide a l'etat supercritique
US6245974B1 (en) 1997-08-06 2001-06-12 North Carolina State University Matrix attachment regions
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US6177612B1 (en) 1998-07-31 2001-01-23 Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada Matrix attachment regions
AU762382B2 (en) 1998-09-29 2003-06-26 Pioneer Hi-Bred International, Inc. MAR/SAR elements flanking RSYN7-driven construct
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100408844B1 (ko) 2000-07-29 2003-12-06 한국산업기술평가원 동물세포 발현벡터
CA2716959A1 (en) * 2000-12-07 2002-06-13 Eli Lilly And Company Glp-1 fusion proteins
AU2002216443A1 (en) 2000-12-15 2002-06-24 Pangen Biotech Inc. Expression vector for animal cell containing nuclear matrix attachment region fointerferon beta
CA2435972C (en) 2001-01-26 2011-09-13 University Of Lausanne Matrix attachment regions and methods for use thereof
PT1454138E (pt) 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
CN1802386B (zh) 2003-06-12 2010-12-15 伊莱利利公司 Glp-1类似物融合蛋白质
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
ATE514783T1 (de) 2003-11-12 2011-07-15 Schering Corp Plasmidsystem zur expression mehrerer gene
KR20070003934A (ko) 2004-03-05 2007-01-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
AU2006244497B2 (en) * 2005-05-06 2011-09-22 Providence Health & Services - Oregon Trimeric OX40L-immunoglobulin fusion protein and methods of use
US20080311078A1 (en) 2005-06-14 2008-12-18 Gokarn Yatin R Self-Buffering Protein Formulations
JP2009500458A (ja) * 2005-07-11 2009-01-08 マクロジェニクス，インコーポレーテッド ヒト化抗ｃｄ１６ａ抗体を用いる自己免疫疾患の治療方法
GB0623539D0 (en) 2006-11-24 2007-01-03 Avidex Ltd Polypeptides
CN101951940A (zh) 2007-03-15 2011-01-19 比奥根艾迪克Ma公司 自身免疫病的治疗
US20090016935A1 (en) 2007-07-09 2009-01-15 Andrianov Alexander K Coating formulations including polyphosphazene polyelectrolytes and biologically active agents and asperities coated with such formulations
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
US8906356B2 (en) * 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
MX2011007647A (es) * 2009-01-21 2011-09-01 Amgen Inc Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
CA2750533A1 (en) * 2009-01-23 2010-07-29 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
WO2011063348A1 (en) 2009-11-23 2011-05-26 Amgen Inc. Monomeric antibody fc
US20130011401A1 (en) * 2009-12-22 2013-01-10 Novartis Ag Soluble proteins for use as therapeutics
TW201305200A (zh) 2010-11-30 2013-02-01 Genentech Inc 低親和力血腦障壁受體抗體及其用途
DK3489255T3 (da) * 2011-02-10 2021-08-23 Roche Glycart Ag Muterede interleukin-2-polypeptider
EP2686345B1 (en) 2011-03-16 2018-04-25 Amgen Inc. Fc variants
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
RU2014136332A (ru) 2012-02-06 2016-03-27 Дженентек, Инк. Композиции и способы применения ингибиторов csf1r
KR102293061B1 (ko) 2012-05-21 2021-08-23 제넨테크, 인크. 혈액-뇌 장벽 수송의 안전성을 개선하는 방법
US9546203B2 (en) * 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
SG11201507429TA (en) * 2013-03-15 2015-10-29 Genentech Inc Il-22 polypeptides and il-22 fc fusion proteins and methods of use
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
WO2014153111A2 (en) 2014-09-25
US10829535B2 (en) 2020-11-10
CA3149348C (en) 2023-09-12
BR112015023145A2 (pt) 2017-11-21
HRP20190970T1 (hr) 2019-07-26
JP7227951B2 (ja) 2023-02-22
BR112015022440A2 (pt) 2017-10-24
JP2016514161A (ja) 2016-05-19
MA38477A1 (fr) 2017-09-29
SG11201507574VA (en) 2015-10-29
EA201591731A1 (ru) 2016-04-29
UA119140C2 (uk) 2019-05-10
PE20151763A1 (es) 2015-12-10
CA3149348A1 (en) 2014-09-25
MY202248A (en) 2024-04-19
AU2014236281A1 (en) 2015-09-24
US20180237489A1 (en) 2018-08-23
WO2014153063A1 (en) 2014-09-25
AP2015008737A0 (en) 2015-09-30
AR095541A1 (es) 2015-10-21
MX2015012890A (es) 2015-12-03
TWI784288B (zh) 2022-11-21
US10562950B2 (en) 2020-02-18
IL241622B (en) 2020-09-30
TWI687435B (zh) 2020-03-11
EA201591766A1 (ru) 2016-02-29
CA2906708C (en) 2022-05-03
CL2015002669A1 (es) 2016-09-09
EP2970441A4 (en) 2016-11-23
CN105358570B (zh) 2019-11-12
TW202005979A (zh) 2020-02-01
LT2970423T (lt) 2019-05-27
EP2970441A1 (en) 2016-01-20
WO2014153111A3 (en) 2014-11-13
JP6480409B2 (ja) 2019-03-13
MA49207B1 (fr) 2022-08-31
PH12015502051B1 (en) 2016-01-18
ES2720225T3 (es) 2019-07-18
US20140286898A1 (en) 2014-09-25
US20170081382A1 (en) 2017-03-23
JP2016518823A (ja) 2016-06-30
KR102418771B1 (ko) 2022-07-08
CL2015002686A1 (es) 2016-04-15
CN105143253A (zh) 2015-12-09
EP2970441B1 (en) 2019-03-06
KR20150127185A (ko) 2015-11-16
US9932380B2 (en) 2018-04-03
JP2021040630A (ja) 2021-03-18
RS58854B1 (sr) 2019-07-31
ME03482B (me) 2020-01-20
NZ751148A (en) 2021-05-28
JO3796B1 (ar) 2021-01-31
JP6450365B2 (ja) 2019-01-09
TR201908362T4 (tr) 2019-06-21
AU2014236281B2 (en) 2018-03-08
KR102219124B1 (ko) 2021-02-22
NZ712066A (en) 2021-05-28
CA2905141A1 (en) 2014-09-25
JP2023053148A (ja) 2023-04-12
US20170137485A1 (en) 2017-05-18
PT2970423T (pt) 2019-07-23
US20210094997A1 (en) 2021-04-01
BR112015022440B1 (pt) 2022-08-16
PT2970441T (pt) 2019-06-11
PL2970441T3 (pl) 2019-09-30
MA49207A1 (fr) 2021-09-30
PH12015502051A1 (en) 2016-01-18
AU2014236316A9 (en) 2018-11-08
US9580486B2 (en) 2017-02-28
AU2014236316A1 (en) 2015-10-08
KR20220101009A (ko) 2022-07-18
TW202115106A (zh) 2021-04-16
SI2970441T1 (sl) 2019-07-31
CY1121823T1 (el) 2020-07-31
MX2015012912A (es) 2015-12-03
HK1220695A1 (zh) 2017-05-12
HRP20191075T1 (hr) 2019-09-20
US9546203B2 (en) 2017-01-17
TN2015000416A1 (en) 2017-01-03
DK2970441T3 (da) 2019-06-03
MY172991A (en) 2019-12-17
LT2970441T (lt) 2019-06-10
CR20150557A (es) 2015-11-10
DK2970423T3 (da) 2019-07-08
US11976102B2 (en) 2024-05-07
IL241349B (en) 2018-08-30
RS58791B1 (sr) 2019-07-31
KR20230157526A (ko) 2023-11-16
AU2014236316B2 (en) 2018-11-01
TW201522366A (zh) 2015-06-16
HUE044321T2 (hu) 2019-10-28
TR201910802T4 (tr) 2019-08-21
HUE043488T2 (hu) 2019-08-28
ME03437B (me) 2020-01-20
SG11201507420UA (en) 2015-10-29
CA2906708A1 (en) 2014-09-25
MX366854B (es) 2019-07-26
CN105143253B (zh) 2021-02-19
US10093711B2 (en) 2018-10-09
TWI709572B (zh) 2020-11-11
ES2737598T3 (es) 2020-01-15
CR20200004A (es) 2020-03-11
CY1121767T1 (el) 2020-07-31
JP2019058182A (ja) 2019-04-18
EA034326B1 (ru) 2020-01-28
IL241349A0 (en) 2015-11-30
EP2970423A2 (en) 2016-01-20
EP2970423B1 (en) 2019-04-24
US20140343252A1 (en) 2014-11-20
MA38477B1 (fr) 2019-05-31
KR20150130342A (ko) 2015-11-23
US20180319859A1 (en) 2018-11-08
CN105358570A (zh) 2016-02-24
SI2970423T1 (sl) 2019-08-30
EA032863B1 (ru) 2019-07-31
PL2970423T3 (pl) 2019-10-31

Similar Documents

Publication Publication Date Title
UY35454A (es) Muteínas de interleucina-2 para la expansión de células t reguladoras
CO2017011487A2 (es) Muteínas de interleuquina 2 para la expansión de células t regulatorias
WO2016164937A3 (en) Interleukin-2 muteins for the expansion of t-regulatory cells
CO2018002450A2 (es) Proteínas de fusión de gitrl y usos de las mismas
PH12019500781A1 (en) IL15/IL15Ra HETERODIMERIC FC-FUSION PROTEINS
CR20140565A (es) Proteínas de fusión de interleuquina 10 y usos de las mismas
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
CL2017002553A1 (es) Muteínas de interleuquina 2 para la expansión de células t regulatorias
MX2015014424A (es) Construcciones de proteinas mitocondriales y sus usos.
AR115695A1 (es) Moléculas proteicas multifuncionales que comprenden decorina y uso de estas
CL2022000355A1 (es) Muteínas de interleucina-2 para la expansión de células t reguladoras
CR20150477A (es) Polipéptidos de il-22 y proteínas de fusión de il-22 fc y métodos de uso
BR112017003074A2 (pt) Célula isolada, e, métodos de produção de uma proteína recombinante de interesse e de glicosilação de um substrato de proteína de n- glicano.
BR112014017788A2 (pt) proteína de fusão de interferona e de seção fc de imunoglobulina
MX2016009636A (es) Montaje de parasol con multiples espejos.

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20231004